Progress in the pursuit of therapeutic adenosine receptor antagonists

Medicinal Research Reviews

Volumn 26, Issue 2, 2006, Pages 131-159

  Moro, Stefano ^a   Gao, Zhan Guo ^b   Jacobson, Kenneth A ^b   Spalluto, Giampiero ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Adenosine receptor; Antagonists; G protein coupled receptor

Indexed keywords

3,7 DIMETHYL 1 PROPARGYL 8 (3 BROMOSTYRYL)XANTHINE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5 AMINO 2 (2 FURYL) 7 (3 PHENYLPROPYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5 AMINO 7 [3 (4 HYDROXYPHENYL)PROPYL] 2 (2 FURYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE DERIVATIVE; 5 AMINO 7 [BETA (4 HYDROXYPHENYL)ETHYL] 2 (2 FURYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE DERIVATIVE; 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENYLATE CYCLASE; ENPROFYLLINE; FR 194921; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HETEROCYCLIC COMPOUND; IMIDAZO[4,5 C]QUINOLIN 4 AMINE DERIVATIVE; ISTRADEFYLLINE; LIGAND; NAXIFYLLINE; PHOSPHOLIPASE C; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINE DERIVATIVE;

CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; MOLECULAR MODEL; NONHUMAN; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; FLAVONOIDS; HETEROCYCLIC COMPOUNDS; HUMANS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUINAZOLINES; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; RECEPTOR, ADENOSINE A2B; RECEPTOR, ADENOSINE A3; RECEPTORS, PURINERGIC P1; TRIAZOLES; XANTHINES;

EID: 33644674438     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20048     Document Type: Review

References (153)

1. Downey JM, Cohen MV, Ytrehus K, Liu Y. Cellular mechanisms in ischemic preconditioning: The role of adenosine and protein kinase Ca. Ann NY Acad Sci 1994;723:82-98.
2. 2B receptor. Mol Pharmacol 1997;52:846-860.
3. Jacobson KA, von Lubitz DKJE, Daly JW, Fredholm BB. Adenosine receptor ligands: Differences with acute versus chronic treatment. Trends Pharmacol Sci 1996;17:108-113.
4. Fredholm BB. Adenosine and neuroprotection. Int Rev Neurobiol 1997;40:259-280.
5. 2B receptors: A novel therapeutic target in asthma? Trends Pharmacol Sci 1998;19:148-153.
6. Fozard JR, McCarthy C. Adenosine receptor ligands as potential therapeutics in asthma. Curr Opin Investig Drugs 2002;3:69-77.
7. 2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci 1997;18:338-344.
8. Ribeiro JA, Sebastiao AM, de Mendonca A. Adenosine receptors in the nervous system: Pathophysiological implications. Prog Neurobiol 2002;68:377-392.
9. Yan L, Burbiel JC, Maass A, Muller CE. Adenosine receptor agonists: From basic medicinal chemistry to clinical development. Expert Opin Emerg Drugs 2003;8:537-576.
10. Fredholm BB. Adenosine receptors as targets for drug development. Drug News Perspect 2003;16:283-289.
11. 3 adenosine receptor as an example. Trends Pharmacol Sci 2005;26:44-51.
12. Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol 2000;362:364-374.
13. 3 receptor subtype. Curr Top Med Chem 2003;3:463-469.
14. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 2003;63:1256-1272.
15. Lefkowitz RJ. Historical review: A brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol Sci 2004;25:413-422.
16. 1 adenosine receptor. Arch Biochem Biophys 1990;283:440-446.
17. 2 adenosine receptor binding subunit. Mol Pharmacol 1990;38:177-183.
18. 2 adenosine receptors by two antipeptide antibody preparations. Mol Pharmacol 1992;42:391-397.
19. 3 adenosine receptor with widespread tissue distribution. Mol Pharmacol 1993;44:524-532.
20. 1 adenosine receptor. Biochem Biophys Res Commun 1992;187:919-926.
21. 2b receptor from human brain. Biochem Biophys Res Commun 1992;187:86-93.
22. 3 adenosine receptor. Proc Natl Acad Sci USA 1993;90:10365-10369.
23. 2 receptor. Mol Brain Res 1992;15:62-66.
24. Fong TM, Strader CD. Functional mapping of the ligand binding sites of G-protein coupled receptors. Med Res Rev 1994;14:387-399.
25. Moro S, Jacobson KA. Molecular modeling as a tool to investigate molecular recognition in P2Y receptors. Curr Pharm Des 2002;8:2401-2413.
26. Pauwels PJ, Wurch T. Review: Amino acid domains involved in constitutive activation of G protein-coupled receptors. Mol Neurobiol 1998;17:109-135.
27. Bockaert J, Pin JP. Molecular tinkering of G protein-coupled receptors: An evolutionary success. EMBO J 1999;7:1723-1729.
28. Mirzadegan T, Benko G, Filipek S, Palczewski K. Sequence analyses of G-protein-coupled receptors: Similarities to rhodopsin. Biochemistry 2003;42:2759-2767.
29. 1 adenosine receptor: Studies on the ligand binding site by site-directed mutagenesis. J Biol Chem 1992;267:10764-10770.
30. 1 adenosine receptor mediates specific agonist binding. J Biol Chem 1994;269:2373-2376.
31. 1 adenosine receptors: Two amino acids are responsible for species differences in ligand recognition. J Biol Chem 1994;269:27900-27906.
32. 1 adenosine receptor: Influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding. Mol Pharmacol 1996;50:1635-1642.
33. 2a adenosine receptor. J Biol Chem 1995;270:13987-13997.
34. 2a adenosine receptor are required for ligand recognition. Mol Pharmacol 1996; 49:683-691.
35. 2A adenosine receptors are required for ligand recognition. Mol Pharmacol 1996;50:512-521.
36. 3 adenosine receptor. J Biol Chem 2002;277:19056-19063.
37. Moro S, Deflorian F, Spalluto G, Pastorin G, Cacciari B, Kim SK, Jacobson KA. Demystifying the three dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modeling. Chem Commun (Camb) 2003;21:2949-2956.
38. Klabunde T, Hessler G. Drug design strategies for targeting G-protein-coupled receptors. Chembiochem 2002;3:928-944.
39. Becker OM, Marantz Y, Shacham S, Inbal B, Heifetz A, Kalid O, Bar-Haim S, Warshaviak D, Fichman M, Noiman S. G protein-coupled receptors: In silico drug discovery in 3D. Proc Natl Acad Sci USA 2004;101:11304-11309.
40. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000;289:739-745.
41. Klotz KN. Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch Pharmacol 2000;362:382-391.
42. 1 adenosine receptor ligands. Curr Top Med Chem 2003;3:369-385.
43. 1 receptor ligands. Curr Top Med Chem 2003;3:355-367.
44. 2A receptor agonists. Curr Top Med Chem 2003;3:387-401.
45. 3 receptor ligands. Curr Top Med Chem 2003;3:445-462.
46. 1 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 1987;336:204-210.
47. Robeva AS, Woodard R, Jin X, Gao Z, Bhattacharya S, Taylor HE, Rosin DL, Linden J. Molecular characterization of recombinant human adenosine receptors. Drug Dev Res 1996;36:243-252.
48. 1 adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxy)norbornyl]xanthine. J Med Chem 1997;40:1773-1778.
49. Jacobson KA, Ukena D, Padgett W, Kirk KL, Daly JW. Molecular probes for extracellular adenosine receptors. Biochem Pharmacol 1987;36:1697-1707.
50. 1-adenosine receptor-antagonist complexes in single living cells. Proc Nat Acad Sci USA 2004;101:4673-4678.
51. 1H-imidazo[4,5-c]quinolin-4-amines: Novel non-xanthine adenosine antagonists. J Med Chem 1991;34:1202-1206.
52. Boehringer Ingelheim Pharm. K.G. Triazolopurines, process for their preparation and their use as medicaments. EP 0978517, 2000; Imidazotriazolopyrimidines. WO oo 12511, 2000.
53. 1 adenosinereceptor antagonists. J Med Chem 2001;44:316-327.
54. Colotta V, Catarzi D, Varano F, Cecchi L, Filacchioni G, Martini C, Trincavelli L, Lucacchini A. 1,2,4-triazolol[4,3-a]quinoxalin-1-one: A versatile tool for the synthesis of potent and selective adenosine receptor antagonists. J Med Chem 2000;43:1158-1164.
55. Colotta V, Catarzi D, Varano F, Cecchi L, Filacchioni G, Martini C, Trincavelli L, Lucacchini A. Synthesis and structure-activity relationships of a new set of 2-arylpyrazolo [3,4-c] quinoline derivatives as adenosine receptor antagonists. J Med Chem 2000;43:3118-3124.
56. 1 adenosine receptor antagonists. Eur J Med Chem 1998;33:943-955.
57. 3 adenosine receptor antagonists. J Med Chem 2000;43:4636-4646.
58. Van Muijlwijk-Koezen JE, Timmerman E, Vollinga RC, Von Frijtag Drabbe Künzel JK, De Groote M, Visser S, IJzerman AP. Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists. J Med Chem 2001;44:749-762.
59. 1 adenosine receptors. Bioorg Med Chem Lett 2001;11:2017-2019.
60. 1 receptor antagonist. Bioorg Med Chem Lett 1999;9:1979-1984.
61. 1 receptor antagonists, synthesis and structure activity relationships of a novel series of 3-(2-Cyclohexenyl-3-oxo-2, 3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines. Bioorg Med Chem 2000;8:55-64.
62. 1 receptor antagonists with high blood-brain barrier permeability. Chem Pharm Bull 2001;49:988-998.
63. 1 adenosine antagonists: Structure-affinity profile of a series of 1,8-naphthyridine derivatives. J Med Chem 2000;43:2814-2823.
64. Ferrarini PL, Betti L, Cavallini T, Gianaccini G, Lucacchini A, Manera C, Martinelli A, Ortore G, Saccomanni G, Tuccinardi T. Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives. J Med Chem 2004;47:3019-3031.
65. 1 receptor antagonists. J Med Chem 2004;47:6529-6540.
66. 1 receptors. J Pharmacol Sci 2004;96:42-52.
67. Dassesse D, Massie A, Ferrari R, Ledent C, Parmentier M, Arckens L, Zoli M, Schiffmann SN. Functional striatal hypodopaminergic activity in mice lacking adenosine A(2A) receptors. J Neurochem 2001;78:183-198.
68. Müller CE, Stein B. Adenosine receptor antagonists: Structures and potential therapeutic applications. Curr Pharm Des 1996;2:501-530.
69. 2A antagonists. J Med Chem 1992;35:2342-2345.
70. 2A receptor antagonist. Eur J Pharmacol Mol Pharm Sect 1994;267:335-341.
71. 2-selective adenosine antagonists. J Med Chem 1993;36:1333-1342.
72. 2 adenosine receptor antagonist in vivo. J Pharmacol Exp Ther 1993;267:1304-1310.
73. 2 antagonist, (E)-1,3-Dipropyl-8-(3, 4-dimethoxystyryl)-7- methylxanthine. J Med Chem 1993;34:3731-3733.
74. 2A adenosine receptor antagonists. Eur J Med Chem 1997;32:709-719.
75. 2A-selective adenosine receptor antagonists. J Med Chem 1997;40:4396-4405.
76. Shamin MT, Ukena D, Padgett WL, Daly JW. Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions. J Med Chem 1989;32:1231-1237.
77. 2A adenosine receptor antagonists. Eur J Med Chem 1996;31:59-63.
78. 2 affinity. J Med. Chem 1991;34:1431-1435.
79. Jacobson KA, Shi D, Gallo-Rodriguez C, Manning M, Jr., Müller C, Daly JW, Neumeyer JL, Kiriasis L, Pfleiderer W. Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors. J Med Chem 1993;36:2639-2644.
80. 2A-selective adenosine receptor antagonists. Bioorg Med Chem 1998;6:707-719.
81. 2A-selective adenosine receptor antagonists. J Med Chem 2000; 43:440-448.
82. Knutsen LJ, Weiss SM. KW-6002 (Kyowa Hakko Kogyo). Curr Opin Invest Drugs 2001;2:668-673.
83. 2A adenosine receptor antagonists with 8-styrylxanthine structure: Potential drugs for Parkinson's disease. J Org Chem 2004;69:3308-3318.
84. Francis JE, Cash WD, Psychoyos S, Ghai G, Wenk P, Friedmann RC, Atkins C, Warren V, Furness P, Hyun JL, Stone GA, Desai M, Williams M. Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists. J Med Chem 1988;31:1014-1020.
85. Williams M, Francis J, Ghai G, Braunwalder A, Psychoyos S, Stone GA, Cash WD. Biochemical characterization of the triazoloquinazoline, CGS 15943, a novel, non-xanthine adenosine antagonist. J Pharmacol Exp Ther 1987;241:415-420.
86. Kim YC, Ji X, Jacobson KA. Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) are selective for the human A3 receptor subtype. J Med Chem 1996;39:4142-4148.
87. 2A adenosine antagonists. J Med Chem 1996;39:1164-1171.
88. 2A adenosine receptor antagonists. J Med Chem 1998;41:2126-2133.
89. 2A receptor system using positron emission tomography. J Med Chem 2000;43:4359-4362.
90. 2A adenosine receptor antagonists: A study on the importance of modifications at the side chain on the activity and solubility. J Med Chem 2002;45:115-126.
91. 2A selective adenosine receptor antagonist. Br J Pharmacol 1995;115:1096-1102.
92. 2B adenosine receptors. Drug Des Discov 1999;16:217-226.
93. 2A receptor antagonists: Comparison of three core heterocycles. Bioorg Med Chem Lett 2004;14:4831-4834.
94. 2A receptor antagonists. Bioorg Med Chem Lett 2004;14:4835-4838.
95. 2A receptor antagonists. J Med Chem 2004;47:4291-4299.
96. 2A receptor antagonists. J Med Chem 2004;47:6218-6229.
97. 2A receptor antagonists. J Med Chem 2005;48:2009-2018.
98. Colotta V, Catarzi D, Varano F, Cecchi L, Filacchioni G, Martini C, Trincavelli L, Lucacchini A. 1,2,4-Triazolo[4,3-a]quinoxalin-1-one: A versatile tool for the synthesis of potent and selective adenosine receptor antagonists. J Med Chem 2000;43:1158-1164.
99. 2A adenosine receptors. Bioorg Med Chem 2000;8:2581-2590.
100. 2A antagonists. Bioorg Med Chem Lett 2005;15:1333-1336.
101. von Lubitz DK. Adenosine in the treatment of stroke: Yes, maybe, or absolutely not? Expert Opin. Investig Drugs 2001;10:619-632.
102. 2A adenosine receptor. Br J Pharmacol 2001;132:37-46.
103. Jacobson KA, Hoffmann C, Cattabeni F, Abbracchio MP. Adenosine-induced cell death: Evidence for receptor-mediated signalling. Apoptosis 1999;4:197-211.
104. Landells LJ, Jensen MW, Orr LM, Spina D, O'Connor BJ, Page CP. The role of adenosine receptors in the action of theophylline on human peripheral blood mononuclear cells from healthy and asthmatic subjects. Br J Pharmacol 2000;129:1140-1144.
105. 2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest 1995;96:1979-1986.
106. Kim SA, Marshall MA, Melman N, Kim SH, Müller CE, Linden J, Jacobson KA. Structure-activity relationships at human and rat adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem 2002;45:2131-2138.
107. 2B-selective adenosine receptor antagonists. J Med Chem 2002;45:1500-1510.
108. Yan L, Müller CE. Preparation, properties and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: Toward the development of sulfonic acid prodrugs with peroral bioavailability. J Med Chem 2004;47:1031-1043.
109. 2B adenosine receptors. Drug Dev Res 1999;47:45-53.
110. 2B adenosine receptors. Drug Dev Res 1999;47:178-188.
111. 2B adenosine receptors. J Med Chem 2000;43:1165-1172.
112. 2B adenosine receptors. Biochem Pharmacol 2001;61:657-663.
113. 2B adenosine receptor antagonists. J Med Chem 2004;47:1434-1447.
114. 2B adenosine receptors. Bioorg Med Chem Lett 2004;14:3607-3610.
115. 2B adenosine receptor antagonist for the potential treatment of asthma. Bioorg Med Chem Lett 2005;15:609-612.
116. 2B. Eur J Med Chem 2004;39:879-887.
117. 3 receptor subtypes. J Med Chem 1998;41:2835-2845.
118. 2B adenosine receptor antagonists. Drug Dev Res 2001;53:225-235.
119. 2B adenosine receptor subtypes: A molecular modeling investigation. J Med Chem 2003;46:4287-4296.
120. 2B adenosine receptors. Drug Des Discov 1999;16:217-226.
121. 2B receptor. Derivatives of the triazolotriazine adenosine receptor antagonist ZM241385 with high affinity. Drug Dev Res 1999;48:95-103.
122. Camaioni E, Costanzi S, Vittori S, Volpini R, Klotz KN, Cristalli G. New substituted 9-alkylpurines as adenosine receptor ligands. Bioorg Med Chem 1998;6:523-533.
123. 2A affinity. Drug Dev Res 2000;50:67.
124. 2B receptors. Bioorg Med Chem 2003;11:77-85.
125. 2B receptors. Biochem Pharmacol 2004;68:315-322.
126. 2B adenosine receptors. Curr Top Med Chem 2003;3:427-443.
127. 2B receptors. J Neurochem 2003;86:220-227.
128. Huang P, Lazarowski ER, Tarran R, Milgram SL, Boucher RC, Stutts MJ. Compartmentalized autocrine signaling to cystic fibrosis transmembrane conductance regulator at the apical membrane of airway epithelial cells. Proc Natl Acad Sci USA 2001;98:14120-14125.
129. 3 adenosine receptor effects cell cycle progression and cell growth. Naunyn-Schmiedeberg's Arch Pharmacol 2000;361:225-234.
130. 3 Adenosine receptor ligands; history and perspectives. Med Res Rev 2000;20:103-128.
131. 3 adenosine receptor antagonists. J Med Chem 2002;45:3337-3344.
132. 3 adenosine receptors. Bioorg Med Chem 2003;11:347-356.
133. 1H-imidazo[2,1-i]-purin-5-one ([(3)H]PSB-11), a novel high-affinity antagonist radioligand for human A(3) adenosine receptors. Bioorg Med Chem Lett 2002;12:501-503.
134. 3 receptor ligands. J Med Chem 2002;45:3703-3708.
135. 3 receptor ligands. Bioorg Med Chem Lett 2004;14:2443-2446.
136. 3 adenosine receptors. In: Doherty AM, editor. Annual report in medicinal chemistry, 1st edition.: Elsevier; 2003;38:121-130.
137. Moro S, van Rhee AM, Sanders LH, Jacobson KA. Flavonoid derivatives as adenosine receptor antagonists: A comparison of the hypothetical receptor binding site based on a comparative molecular field analysis model. J Med Chem 1998;41:46-52.
138. 3 adenosine receptor-selective antagonists. Neuropharmacology 1997;36:1157-1165.
139. 3 adenosine receptor antagonists. J Med Chem 1997;40:2596-2608.
140. 3 adenosine receptor antagonists. J Med Chem 1999;42:706-721.
141. 3-adenosine receptors. Drug Dev Res 1994;33:51-59.
142. 3 receptor subtype. J Med Chem 1996;39:4142-4148.
143. 3 receptor ligands. 2. Stucture affinity profile of a series of isoquinoline and quinazoline compounds. J Med Chem 1998;41:3994-4000.
144. 3 receptor. J Med Chem 2000;43:2227-2238.
145. 3 adenosine receptor antagonists. J Med Chem 2002;45:770-780.
146. 3 adenosine receptor antagonist. J Med Chem 2002;45:3579-3582.
147. 3 adenosine receptor antagonists: Synthesis, pharmacological, and ligand-receptor modeling studies. J Med Chem 2004;47:3580-3590.
148. 3 adenosine receptor antagonists. Bioorg Med Chem 2005;13:705-715.
149. 3 adenosine receptor antagonists. Drug Dev Res 1996;37:131.
150. 3 receptor antagonists. Bioorg Med Chem 2004;12:613-623.
151. 3 adenosine receptor activation: Nucleoside ligands at the agonist/antagonist boundary. J Med Chem 2002;45:4471-4484.
152. Costanzi S, Lambertucci C, Vittori S, Volpini R, Cristalli G. 2-and 8-alkynyladenosines: Conformational studies and docking to human adenosine A(3) receptor can explain their different biological behavior. J Mol Graph Mod 2003;21:253-262.
153. 3 receptor ligands: New potential therapy for the treatment of glaucoma. Bioorg Med Chem Lett 2004;14:3775-3779.